RESUMEN
A specific and sensitive liquid chromatography tandem mass spectrometry (LC-MS/MS) method was developed and validated for the analysis of glaucocalyxin A and glaucocalyxin B in rat plasma using praeruptorin A as an internal standard. Separation was performed on a Hypurity C18 column (2.1 × 50 mm, 5 µm) with isocratic elution using 0.2% formic acid in water-acetonitrile (20:80, v/v). Mass spectrometric detection was conducted using selected reaction monitoring via an electrospray ionization source. Both analytes exhibited good linearity within their concentration ranges (r2 > 0.9932). The lower limit of quantitation of glaucocalyxin A and glaucocalyxin B was 1.10 ng/mL. Intra- and inter-day precision exhibited an RSD within 14.5%, and the accuracy (RE) ranged from -12.1 to 15.0% at the lower limit of quantitation and three quality control levels. The developed assay was successfully applied to a pharmacokinetic study of glaucocalyxin A and glaucocalyxin B in rats after oral administration of Rabdosia japonica extract.
Asunto(s)
Cromatografía Liquida/métodos , Diterpenos de Tipo Kaurano/sangre , Isodon/química , Extractos Vegetales/administración & dosificación , Espectrometría de Masas en Tándem/métodos , Administración Oral , Animales , Diterpenos de Tipo Kaurano/química , Diterpenos de Tipo Kaurano/farmacocinética , Estabilidad de Medicamentos , Límite de Detección , Modelos Lineales , Extractos Vegetales/farmacocinética , Ratas , Ratas Wistar , Reproducibilidad de los ResultadosRESUMEN
To improve the solubility and bioavailability of oridonin (ORI), glycerol monooleate lipid (GMO)- or phytantriol (PYT)-Poloxamer 407-propylene glycol-water systems were firstly used to develop cubosomes containing ORI for oral delivery. These cubosomes prepared through the fragmentation of bulk gels under homogenization conditions of 1200 bar and nine cycles had a mean particle size of around 200 nm with narrow size distribution, and ORI encapsulation efficiency over 85%. Powder X-ray diffraction and differential scanning calorimetry indicated that ORI was in an amorphous or molecular form in the cubosomes. The internal structures of GMO- and PYT-based cubosomes were revealed by small-angle X-ray scattering as a bi-continuous cubic liquid crystalline phase with Im3m and Pn3m geometry, respectively. About 80% of ORI was released in vitro from GMO- and PYT-based cubosomes at 24 h, showing a sustained release kinetics fitted with Higuchi's equation. The pharmacokinetic study in rats showed that the PYT-based cubosomes significantly enhanced the adsorption of ORI as compared to the GMO-based cubosomes and ORI suspension, with evidence of longer half-life and greater relative bioavailability (p < 0.01). Therefore, the PYT-based cubosomes containing ORI might be proposed as a promising candidate carrier for the efficient delivery of drug with therapeutic treatment.
Asunto(s)
Diterpenos de Tipo Kaurano/administración & dosificación , Portadores de Fármacos/química , Composición de Medicamentos/métodos , Medicamentos Herbarios Chinos/administración & dosificación , Alcoholes Grasos/química , Glicéridos/química , Administración Oral , Animales , Diterpenos de Tipo Kaurano/sangre , Diterpenos de Tipo Kaurano/química , Relación Dosis-Respuesta a Droga , Liberación de Fármacos , Medicamentos Herbarios Chinos/química , Medicamentos Herbarios Chinos/farmacocinética , Estructura Molecular , Tamaño de la Partícula , Ratas Endogámicas , Propiedades de SuperficieRESUMEN
An intravenously injectable liquid formulation of the poorly water-soluble isosteviol sodium (ISVNa) that has a great clinical potential for cardiovascular diseases was developed using the co-solvent technology. The pH and composition of the co-solvent were optimized to obtain a stable liquid formulation (termed as STVNa) based on saline at pH 10.0 containing 25% (v/v) of ethanol and 20% (v/v) of propylene glycol. STVNa was physicochemically stable upon storage for more than 3 months under various conditions. In vitro studies showed that STVNa did not induce hemolytic effects up to 9.1% (v/v) after 3 h of incubation and it was cytocompatible up to 50 µg/mL in H2C9 cells. Furthermore, STVNa showed acceptable safety and pharmacokinetic parameters comparable with those of ISVNa in saline (dissolved at 60 °C) upon i.v. injection in Wistar rats. Overall, the results demonstrated that STVNa is a promising formulation of ISVNa for clinical translation.
Asunto(s)
Diterpenos de Tipo Kaurano/administración & dosificación , Diterpenos de Tipo Kaurano/sangre , Etanol/química , Vehículos Farmacéuticos/química , Propilenglicol/química , Administración Intravenosa , Animales , Línea Celular , Diterpenos de Tipo Kaurano/química , Composición de Medicamentos , Estabilidad de Medicamentos , Etanol/toxicidad , Hemólisis/efectos de los fármacos , Humanos , Concentración de Iones de Hidrógeno , Vehículos Farmacéuticos/toxicidad , Propilenglicol/toxicidad , Ratas Wistar , Solubilidad , Solventes/química , Solventes/toxicidad , Agua/químicaRESUMEN
OBJECTIVE: The purpose of this study was to develop a new formulation to enhance the bioavailability simultaneously with controlled release of glaucocalyxin A (GLA). MATERIAL AND METHODS: In this study, controlled release of GLA was achieved by the osmotic release strategy taking advantage of the bioavailability enhancing capacity of self-nanoemulsifying drug delivery systems (SNEDDS). The formulation of GLA-SNEDDS was selected by the solubility and pseudoternary-phase diagrams studies. The prepared GLA-SNEDDS formulations were characterized for self-emulsification time, effect of pH and robustness to dilution, droplet size analysis and zeta potential. The optimized GLA-SNEDDS were used to prepare GLA-SNEDDS osmotic pump tablet via direct powder compression method. The effect of formulation variables on the release characteristic was investigated. GLA-SNEDDS osmotic pump tablets were administered to beagle dogs and their pharmacokinetics were compared to GLA and GLA-SNEDDS as a control. RESULTS: In vitro drug release studies indicated that the GLA-SNEDDS osmotic pump tablet showed sustained release profiles with 90% released within 12 h. Pharmacokinetic study showed steady blood GLA with prolonged Tmax and mean residence time (MRT), and enhanced bioavailability for GLA-SNEDDS osmotic pump tablet. CONCLUSION: It was concluded that simultaneous controlling on GLA release and enhanced bioavailability had been achieved by a combination of osmotic pump tablet and SNEDDS.
Asunto(s)
Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/sangre , Preparaciones de Acción Retardada/química , Diterpenos de Tipo Kaurano/administración & dosificación , Diterpenos de Tipo Kaurano/sangre , Animales , Antiinflamatorios no Esteroideos/química , Disponibilidad Biológica , Diterpenos de Tipo Kaurano/química , Perros , Emulsiones/química , Excipientes/química , Ósmosis , Transición de Fase , Solubilidad , ComprimidosRESUMEN
The acceptable daily intake (ADI) of commercially available steviol glycosides is currently 0-4 mg/kg body weight (bw)/day, based on application of a 100-fold uncertainty factor to a no-observed-adverse-effect-level value from a chronic rat study. Within the 100-fold uncertainty factor is a 10-fold uncertainty factor to account for inter-species differences in toxicokinetics (4-fold) and toxicodynamics (2.5-fold). Single dose pharmacokinetics of stevioside were studied in rats (40 and 1000 mg/kg bw) and in male human subjects (40 mg/kg bw) to generate a chemical-specific, inter-species toxicokinetic adjustment factor. Tmax values for steviol were at â¼8 and â¼20 h after administration in rats and humans, respectively. Peak concentrations of steviol were similar in rats and humans, while steviol glucuronide concentrations were significantly higher in humans. Glucuronidation in rats was not saturated over the dose range 40-1000 mg/kg bw. The AUC0-last for steviol was approximately 2.8-fold greater in humans compared to rats. Chemical-specific adjustment factors for extrapolating toxicokinetics from rat to human of 1 and 2.8 were established based on Cmax and AUC0-last data respectively. Because these factors are lower than the default value of 4.0, a higher ADI for steviol glycosides of between 6 and 16 mg/kg bw/d is justified.
Asunto(s)
Diterpenos de Tipo Kaurano/farmacocinética , Diterpenos de Tipo Kaurano/toxicidad , Glucósidos/farmacocinética , Glucósidos/toxicidad , Nivel sin Efectos Adversos Observados , Edulcorantes/farmacocinética , Edulcorantes/toxicidad , Pruebas de Toxicidad/métodos , Toxicocinética , Adulto , Animales , Área Bajo la Curva , Biotransformación , Diterpenos de Tipo Kaurano/sangre , Relación Dosis-Respuesta a Droga , Femenino , Glucósidos/sangre , Glucurónidos/farmacocinética , Semivida , Humanos , Hidrólisis , Masculino , Tasa de Depuración Metabólica , Persona de Mediana Edad , Modelos Biológicos , Ratas , Ratas Sprague-Dawley , Medición de Riesgo , Especificidad de la Especie , Incertidumbre , Adulto JovenRESUMEN
In this paper, a sensitive, rapid and reproducible high-performance liquid chromatography-tandem mass spectrometry method was developed to analyze 16α-hydro-ent-kauran-17,19-dioic acid in rat plasma. First, this study compared the pharmacokinetics of 16α-hydro-ent-kauran-17,19-dioic acid after oral administration of monomer and Siegesbeckiae pubescens Makino extract in rat plasma with approximately the same dosage of 6.0 mg/kg. Second, chromatographic separation was performed on a Waters Symmetry C18 column (2.1 × 100 mm, 3.5 µm) with isocratic elution using methanol-water containing 5 mmol/L ammonium acetate (70:30, v/v) as mobile phase at a flow rate of 0.2 mL/min. The calibration curves were linear over the range of 30-12000 ng/mL for monomer. At different time points (0, 0.083, 0.25, 0.75, 1, 2, 4, 6, 8, 12, 18, 24, 36, 48, 60 and 72 h) after administration, the concentrations of monomer in rat plasma were determined and main pharmacokinetic parameters were estimated. The double absorption presented in this study indicates that the pharmacokinetics of monomer in rat plasma have significant differences between different groups.
Asunto(s)
Asteraceae/química , Cromatografía Líquida de Alta Presión/métodos , Diterpenos de Tipo Kaurano/farmacocinética , Extractos Vegetales/farmacocinética , Espectrometría de Masas en Tándem/métodos , Administración Oral , Animales , Diterpenos de Tipo Kaurano/administración & dosificación , Diterpenos de Tipo Kaurano/sangre , Masculino , Extractos Vegetales/administración & dosificación , Extractos Vegetales/sangre , Ratas , Ratas Sprague-DawleyRESUMEN
A sensitive, specific, and rapid liquid chromatography-mass spectrometry (LC-MS) method was developed and validated for analysis of lasiodonin, oridonin, ponicidin, and rabdoternin A in rat plasma using sulfamethoxazole as an internal standard (IS). The plasma samples were pretreated and extracted by liquid-liquid extraction. Chromatographic separation was performed on a C(18) column with linear gradient elution using water and methanol, both of which were acidified with 0.1% aqueous formic acid, at a flow rate of 0.8 ml/min. Detection was accomplished by scanning with multiple reaction monitoring (MRM) via an electrospray ionization (ESI) source. Higher sensitivity was achieved by setting three scanning periods in a novel detection mode. The optimized mass transition ion pairs (m/z) for quantitation were 365.3/347.3 for lasiodonin and oridonin, 361.2/343.2 for ponicidin, 363.2/283.1 for rabdoternin A, and 254.1/156.0 for IS. The total run time was 13.50 min between injections. The specificity, linearity, accuracy, precision, recovery, matrix effect, and several stabilities were validated for all analytes in the rat plasma samples. In conclusion, the validation results demonstrate that this method is robust and specific. The proposed method was further applied to investigate the pharmacokinetics of all analytes after a single oral administration of Isodon rubescens extract to rats.
Asunto(s)
Cromatografía Líquida de Alta Presión/métodos , Diterpenos/sangre , Espectrometría de Masa por Ionización de Electrospray/métodos , Administración Oral , Animales , Antiinfecciosos/sangre , Antiinfecciosos/farmacocinética , Diterpenos/farmacocinética , Diterpenos de Tipo Kaurano/sangre , Diterpenos de Tipo Kaurano/farmacocinética , Isodon/química , Masculino , Ratas , Ratas Sprague-Dawley , Reproducibilidad de los Resultados , Sulfametoxazol/sangre , Sulfametoxazol/farmacocinéticaRESUMEN
Glaucocalyxin A, a novel potent negative Akt regulator, is a major active constituent of Rabdosia japonica. A simple, specific and sensitive ultra-high pressure liquid chromatography tandem mass spectrometry (UHPLC-MS/MS) method was developed and validated for the quantification of glaucocalyxin A in rat plasma, lung and brain tissues after intravenous administration. Sample preparation was carried out through a simple liqiud-liquid extraction with ethyl acetate using bullatine A as internal standard. The chromatographic separation was achieved by using an Agilent ZORBAX Eclipse Plus C18 column (3.0 mm × 100 mm, 1.8 µm) with a mobile phase of acetonitrile and water containing 0.1% formic acid in a gradient elution. Mass spectrometry analysis was conducted in positive ionization mode with multiple reaction monitoring transitions at m/z 333.2 â 157.1 for glaucocalyxin A and m/z 344.2 â 128.1 for IS. Calibration curves were linear over the ranges of 20.0-4000 ng/mL for both plasma and tissue samples (r2 > 0.99). The Lower limit of quantification (LLOQ) was 0.284 ng/mL. The intra-day and inter-day precision relative standard deviation (RSD%) were <14.9%, while the accuracy ranged from -12.5 to 17.0% for LLOQ and quality control samples. This UHPLC-MS/MS method was successfully applied in the pharmacokinetics, lung and brain tissue distributions of glaucocalyxin A after intravenous administration.
Asunto(s)
Cromatografía Líquida de Alta Presión/métodos , Diterpenos de Tipo Kaurano/sangre , Diterpenos de Tipo Kaurano/farmacocinética , Espectrometría de Masas en Tándem/métodos , Administración Intravenosa , Animales , Encéfalo/efectos de los fármacos , Química Encefálica , Diterpenos de Tipo Kaurano/administración & dosificación , Estabilidad de Medicamentos , Límite de Detección , Pulmón/química , Pulmón/efectos de los fármacos , Proteínas Proto-Oncogénicas c-akt/metabolismo , Ratas Sprague-Dawley , Distribución TisularRESUMEN
A simple and sensitive HPLC method has been developed and validated for the determination of oridonin (ORI) in rabbit plasma. A simple liquid-liquid extraction (LLE) method was applied to extract ORI and the internal standard (IS), isopsoralen, from rabbit plasma. Chromatographic separation of ORI and the IS was achieved with a Kromasil C18 5-mum column (250 mm x 4.6 mm) using methanol-water (50:50, v/v) as mobile phase at a flow rate of 1 mL/min. The ultraviolet (UV) detection wavelength was set at 241 nm. The lower limit of quantification (LLOQ) was 0.02 microg/mL. The calibration curves were linear over a concentration range of 0.02-10 microg/mL. The assay accuracy and precision were within the range of 95.1-113.5% and 5.4-8.6%, respectively. This HPLC method was applied successfully to the pharmacokinetic study of ORI-loaded poly(caprolactone)-poly(ethylene oxide)-poly(caprolactone) copolymer nanoparticles (ORI-PCL-PEO-PCL-NP) in rabbits, given as a single intravenous injection at the dose equivalent to 2mg of ORI/kg, and the pharmacokinetic parameters for ORI were compared with a single intravenous injection of a ORI solution at the same dose.
Asunto(s)
Antineoplásicos Fitogénicos/sangre , Cromatografía Líquida de Alta Presión/métodos , Diterpenos de Tipo Kaurano/sangre , Animales , Antineoplásicos Fitogénicos/administración & dosificación , Antineoplásicos Fitogénicos/farmacocinética , Calibración , Cromatografía Líquida de Alta Presión/normas , Diterpenos de Tipo Kaurano/administración & dosificación , Diterpenos de Tipo Kaurano/farmacocinética , Furocumarinas/sangre , Furocumarinas/química , Inyecciones Intravenosas , Nanopartículas/administración & dosificación , Poliésteres/administración & dosificación , Conejos , Estándares de ReferenciaRESUMEN
Oridonin, a diterpenoid, is a sparingly soluble compound and its aqueous solubility can't meet the requirement of clinical intravenous administration. This study was, accordingly, to prepare an inclusion complex of oridonin and 2-hydroxypropyl-beta-cyclodextrin (HP-beta-CD) by lyophilization to improve its apparent solubility. The solubility enhancement of oridonin was evaluated by phase solubility method, and the phase solubility curve displayed a typical A(L)-type, indicating the formation of 1:1 inclusion complex. The formation of inclusion complex was confirmed by DSC, XRD, FTIR, and NMR, and thereby two possible inclusion modes were inferred. In vivo studies demonstrated that HP-beta-CD had no significant effect on the plasma pharmacokinetic behaviors of oridonin following i.v. administration to rats, but the inclusion complex tended to decrease the distribution of oridonin in heart, spleen, and kidney and increase that in lung in mice, compared to that of free drug.
Asunto(s)
Diterpenos de Tipo Kaurano/química , Diterpenos de Tipo Kaurano/farmacocinética , Excipientes/química , beta-Ciclodextrinas/química , 2-Hidroxipropil-beta-Ciclodextrina , Animales , Área Bajo la Curva , Disponibilidad Biológica , Rastreo Diferencial de Calorimetría , Química Farmacéutica , Diterpenos de Tipo Kaurano/sangre , Liofilización , Inyecciones Intravenosas , Espectroscopía de Resonancia Magnética , Masculino , Ratones , Ratas , Ratas Wistar , Solubilidad , Espectroscopía Infrarroja por Transformada de Fourier , Distribución Tisular , Difracción de Rayos XRESUMEN
A method for quantitative determination of oridonin in rat plasma using reversed-phase high-performance liquid chromatography (RP-HPLC) coupled with UV spectrometry was established and the method was applied to a pharmacokinetics study of oridonin in rats. From a variety of compounds and solvents tested, ticolpidine was selected as the internal standard (IS) and ethyl acetate was found to be the best solvent for extracting oridonin from plasma samples. RP-HPLC analysis of the extracts was performed on an analytical column (DIKMA ODS, 200 mm x 4.6 mm; i.d., 5 microm) equipped with a security guard pre-column system. There was a good linearity over the range 0.05-8.0 microg/mL (r>0.99). The recoveries were about 95.0% in plasma, and the intra- and inter-day coefficients of variation were less than 9.0% in all cases. The limit of detection (LOD) was 0.025 microg/mL and the lower limit of quantification (LLOQ) was 0.05 microg/mL. The RP-HPLC method was readily applied to quantitate oridonin in rat plasma within 24 h in a pharmacokinetics study where experimental rats received a single dose of oridonin (12.5 mg/kg) and the result was presented.
Asunto(s)
Cromatografía Líquida de Alta Presión/métodos , Diterpenos de Tipo Kaurano/sangre , Diterpenos/sangre , Isodon/química , Espectrofotometría Ultravioleta/métodos , Acetatos/química , Animales , Cromatografía Líquida de Alta Presión/normas , Diterpenos/aislamiento & purificación , Diterpenos/farmacocinética , Diterpenos de Tipo Kaurano/aislamiento & purificación , Diterpenos de Tipo Kaurano/farmacocinética , Modelos Lineales , Masculino , Estructura Molecular , Hojas de la Planta , Ratas , Ratas Wistar , Estándares de Referencia , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Solventes/química , Espectrofotometría Ultravioleta/normasRESUMEN
A sensitive, specific and rapid liquid chromatography-mass spectrometry (LC-MS) method was developed and validated for analysis of ginsenoside Rb1, naringin, ginsenoside Rb2 and oridonin in rat plasma using sulfamethoxazole as an internal standard (IS). Separation was conducted out on an Agilent Eclipse XDB C18 column with liner gradient elution using acetonitrile (A) and 0.1% aqueous acetic acid (B). A tandem mass spectrometric detection was conducted using multiple reaction monitoring (MRM) via an electrospray ionization (ESI) source. A novel multi-determination-periods program was executed to achieve a higher sensitivity by setting three scanning periods. All analytes exhibited good linearity within the concentration range (r>0.9973). The lower limits of quantitation (LLOQ) of ginsenoside Rb1, naringin, ginsenoside Rb2 and oridonin were 2.64, 4.32, 2.32 and 1.56ng/mL, respectively. Intra-day and inter-day precisions of the investigated components exhibited an RSD within 8.3%, and the accuracy (RE) ranged from -8.6% to 6.0% at all quality control levels. The developed method was successfully applied to a pharmacokinetic study of ginsenoside Rb1, naringin, ginsenoside Rb2 and oridonin in rats after oral administration of a Weifuchun tablet.
Asunto(s)
Diterpenos de Tipo Kaurano/sangre , Medicamentos Herbarios Chinos/administración & dosificación , Flavanonas/sangre , Ginsenósidos/sangre , Administración Oral , Animales , Cromatografía Liquida/métodos , Diterpenos de Tipo Kaurano/química , Diterpenos de Tipo Kaurano/farmacocinética , Medicamentos Herbarios Chinos/farmacocinética , Flavanonas/química , Flavanonas/farmacocinética , Ginsenósidos/química , Ginsenósidos/farmacocinética , Modelos Lineales , Masculino , Ratas , Ratas Sprague-Dawley , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Espectrometría de Masas en Tándem/métodosRESUMEN
A rapid and specific liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) method was developed for the simultaneous determination of two active diterpenoids: Kirenol and ent-16ß,17-dihydroxy-kauran-19-oic acid (DHKA) from Herba Siegesbeckiae in rat plasma using osthole as an internal standard (IS). Plasma sample pretreatment involved a one-step liquid-liquid extraction with ethyl acetate. Chromatographic separation was performed on a Waters Symmetry C18 column (2.1mm×100mm, 3.5µm) with isocratic elution using methanol-5mmol/L aqueous ammonium acetate (80:20, v/v) as the mobile phase at a flow rate of 0.2mL/min. The detection was performed on a triple quadrupole tandem mass spectrometer in multiple reaction monitoring (MRM) mode under positive and negative electrospray ionization. The calibration curves were linear over the range of 50.0-25,000ng/mL for Kirenol, and 25.0-12,500ng/mL for DHKA. The extraction recoveries of the two analytes and the IS were all over 85%. The intra- and inter-day precision (relative standard deviation) values were less than 16.8% and the accuracy (relative error) ranged from -10.7 to 10.6% at four quality control levels. The validated method was successfully applied to a comparative pharmacokinetic study of the two diterpenoids in rat plasma after intragastric administration of Kirenol, DHKA and Herba Siegesbeckiae extract. The results showed that there were obvious differences between the pharmacokinetic behaviors after oral administration of Herba Siegesbeckiae extract compared with each of the substances alone.
Asunto(s)
Asteraceae/química , Cromatografía Liquida/métodos , Diterpenos de Tipo Kaurano/sangre , Diterpenos/sangre , Espectrometría de Masas en Tándem/métodos , Animales , Cumarinas/sangre , Cumarinas/química , Diterpenos/química , Diterpenos/farmacocinética , Diterpenos de Tipo Kaurano/química , Diterpenos de Tipo Kaurano/farmacocinética , Estabilidad de Medicamentos , Modelos Lineales , Masculino , Extractos Vegetales/química , Ratas , Ratas Sprague-Dawley , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Espectrometría de Masa por Ionización de Electrospray/métodosRESUMEN
The purpose of this study was to develop poly(ethylene glycol)-coated nanostructured lipid carriers (PEG-NLC) for parenteral delivery of oridonin (ORI) to prolong drug circulation time in blood. Oridonin-loaded PEG-NLC (ORI-PEG-NLC) consisting of PEG(2000)-stearate, glycerol monostearate and medium chain triglycerides were prepared by emulsion-evaporation and low temperature-solidification technique. Oridonin-loaded NLC (ORI-NLC) were also prepared as control. ORI-PEG-NLC were observed by transmission election microscope and the morphology was in rotiform shape. The mean particle size of ORI-PEG-NLC was 329.2 nm and entrapment efficacy was 71.18%. The results of differential scanning calorimetry and X-ray diffraction revealed a low-crystalline structure of ORI and verified the incorporation of ORI into the nanoparticles. In vitro drug release of ORI-PEG-NLC exhibited biphasic drug release patterns with burst release initially and prolonged release afterwards. Pharmacokinetic analysis showed that the mean residence time of ORI-PEG-NLC was prolonged and AUC (area under tissue concentration-time curve) value was also improved compared with ORI-NLC and ORI solution. In conclusion, ORI-PEG-NLC could be a potential carrier to get prolonged retention time of oridonin in blood.
Asunto(s)
Antineoplásicos/química , Antineoplásicos/farmacocinética , Diterpenos de Tipo Kaurano/química , Diterpenos de Tipo Kaurano/farmacocinética , Portadores de Fármacos/química , Lípidos/química , Nanoestructuras/química , Animales , Antineoplásicos/sangre , Tiempo de Circulación Sanguínea , Diterpenos de Tipo Kaurano/sangre , Tamaño de la Partícula , Polietilenglicoles/química , Ratas , Ratas Sprague-Dawley , SolubilidadRESUMEN
In this study, oridonin-loaded nanoparticles coated with galactosylated chitosan (ORI-GC-NP) were prepared for tumor targeting and their characteristics were evaluated for the morphologies, particle size and zeta potential. Oridonin-loaded nanoparticles (ORI-NP) without galactosylated chitosan were prepared as a control. The entrapment efficiency of ORI-GC-NP and ORI-NP were 72.15% and 85.31%, respectively. The in vitro drug release behavior from nanoparticles displayed biphasic drug release pattern with initial burst release and consequently sustained release. Next, the pharmacokinetics and tissue distribution of ORI-GC-NP, ORI-NP and ORI solution were carried out. Pharmacokinetic analysis showed that ORI-GC-NP and ORI-NP could prolong the drug plasma levels compared with ORI solution. Meanwhile, the distribution of ORI-GC-NP to liver was higher than that of ORI-NP and free drug. In conclusion, ORI-GC-NP, as a promising intravenous drug delivery system for ORI, could be developed as an alternative to the conventional ORI preparations.
Asunto(s)
Antineoplásicos/administración & dosificación , Quitosano/administración & dosificación , Diterpenos de Tipo Kaurano/administración & dosificación , Portadores de Fármacos/administración & dosificación , Hepatocitos/metabolismo , Animales , Antineoplásicos/sangre , Antineoplásicos/farmacocinética , Área Bajo la Curva , Quitosano/química , Quitosano/farmacocinética , Diterpenos de Tipo Kaurano/sangre , Diterpenos de Tipo Kaurano/farmacocinética , Portadores de Fármacos/química , Portadores de Fármacos/farmacocinética , Galactosa/química , Ratones , Nanopartículas/administración & dosificación , Nanopartículas/química , Ratas , Ratas Sprague-Dawley , Distribución TisularRESUMEN
OBJECTIVE: The purpose of this study was to develop an active targeting strategy to improve the therapeutic antitumor efficacy of oridonin (ORI), the main active ingredient in the medicinal herb Rabdosia rubescens. METHODS: A modified spontaneous emulsification solvent diffusion method was used to prepare the ORI-loaded atactic poly(D,L-lactic acid) nanoparticles (ORI-PLA-NPs). Surface cross-linking with the peptide Arg-Gly-Asp (RGD) further modified the ORI-PLA-NPs, generating ORI-PLA-RGD-NPs. The NPs were characterized and release experiments were performed in vitro. The pharmacokinetics, tissue distribution, and antitumor activity of the NPs were studied in mice bearing hepatocarcinoma 22 (H22)-derived tumors. RESULTS: The ORI-PLA-NPs and ORI-PLA-RGD-NPs were smooth, sphere-like, and relatively uniform in size. The RGD surface modification slightly increased the mean particle size (95.8 nm for ORI-PLA-NPs versus 105.2 nm for ORI-PLA-RGD-NPs) and considerably altered the surface electrical property (-10.19 mV for ORI-PLA-NPs versus -21.95 mV for ORI-PLA-RGD-NPs), but it had no obvious influence on ORI loading (8.23% ± 0.35% for ORI-PLA-NPs versus 8.02% ± 0.38% for ORI-PLA-RGD-NPs), entrapment efficiency (28.86% ± 0.93% for ORI-PLA-NPs versus 28.24% ± 0.81% for ORI-PLA-RGD-NPs), or the release of ORI. The pharmacokinetic properties of free ORI were improved by encapsulation in NPs, as shown by increased area under the concentration-time curve (11.89 ± 0.35 µg·mL(-1) · h for ORI solution versus 22.03 ± 0.01 µg · mL(-1) · h for ORI-PLA-RGD-NPs) and prolonged mean retention time (2.03 ± 0.09 hours for ORI solution versus 8.68 ± 0.66 hours for ORI-PLA-RGD-NPs). In the tissue distribution study, more ORI targeted tumor tissue in the mice treated with ORI-PLA-RGD-NPs than with ORI-PLA-NPs or ORI solution. Consistent with these observations, ORI-PLA-RGD-NPs showed greater antitumor efficacy than ORI-PLA-RGD-NPs or ORI solution, as reflected by the decreased tumor growth and the prolonged survival time of mice bearing H22 tumors. CONCLUSION: The tumor-targeting efficiency and subsequent antitumor efficacy of ORI is increased by incorporation into ORI-PLA-RGD-NPs.